A phase I study of E7050 in subjects with solid tumors

INTERVENTION: Intervention name : E7050 Dosage And administration of the intervention : oral CONDITION: solid tumor, gastric cancer PRIMARY OUTCOME: Investigation of tolerability and safety of E7050 administered continuously once daily for 4 weeks to subjects with solid tumor and gastric cancer. INCLUSION CRITERIA: 1. Aged from 20 to less than 75 years old at the time of obtaining informed consent. 2. Histological or cytological diagnosis of solid tumors. 3. Subjects who have progressed after treatment with approved therapies or for whom there are no standard effective therapies available. 4. Adequate organ function. 5. Subjects who have no carryover of effect from prior therapy or no adverse drug reactions (excluding alopecia) that may affect the safety evaluation of the investigational drug. 6. Performance Status (PS) 0‐1 established by Eastern Cooperative Oncology Group (ECOG). 7. Expected to survive for 3 months or longer after starting administration of the investigational drug.